I'm sure there's a signed agreement with Synergy.
It's a Distribution Agreement, just like the dozens of distribution agreements BIEL has signed in the past. No guarantee of performance, no guarantee of sales, no guarantee of ANYTHING on Synergy's part -- just a promise to TRY selling RecoveryRx.
And they will probably sell a few. Certainly, no where near 975,000, but they'll sell some. I'm guessing they'll place an initial stocking order of around 15,000 - 30,000 units, and who knows, they might even sell that many, eventually. That's a lot of RecoveryRx though.
I don't know Synergy's price or BIEL's margins, but I won't be surprised if the initial stocking order is around $300,000 gross. That would still be big for BIEL.
Of course, with the shipping issues, chip shortages, supply chain issues, inflation, stock market decline, election year worries, abortion issues, Russian war, Korean missile launches, and all the other "yeah but" external forces causing BIEL's revenue decline, the initial stocking order might be less. LOL
Let's just hope the initial shipping order happens in Q4. Otherwise, Q4 is going to be ugly like Q4 2021. We're already dismissing Q3 as inconsequential as we hitch our wagons to Synergy. Sure, that means dismissing the OEM Partners as inconsequential, but that was a given after the disturbing low revenues in Q4 2021. It's certainly a relief to have the Synergy hype upon which to hitch our wagons.
News 
Market Data 
Discover 
AI
